Trial record 1 of 1 for:    CLBH589BUS48T
Previous Study | Return to List | Next Study

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) (BUS48T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01504776
Recruitment Status : Completed
First Posted : January 5, 2012
Last Update Posted : September 19, 2014
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Anand Jillella, Augusta University

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2014
  Actual Study Completion Date : September 2014